The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment

Autor: Juhász, Szilvia, Smith, Rebecca, Schauer, Tamás, Spekhardt, Dóra, Mamar, Hasan, Zentout, Siham, Chapuis, Catherine, Huet, Sébastien, Timinszky, Gyula

Publikováno v: Science Advances
Science Advances, 2020, 6 (51), ⟨10.1126/sciadv.abb8626⟩
Science Advances, American Association for the Advancement of Science (AAAS), 2020, 6 (51), ⟨10.1126/sciadv.abb8626⟩

International audience; Poly(ADP-ribose) polymerase (PARP) inhibitors are used in the treatment of BRCA-deficient cancers, with treatments currently extending toward other homologous recombination defective tumors. In a genome-wide CRISPR knockout sc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4046cf363f2bcbf035573f5f2cdc8575
https://hal.science/hal-03099309